Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations

Eline W. Muilwijk; Bart G. J. Dekkers; Stefanie S. V. Henriet; Paul E. Verweij; Bregje Witjes; Astrid M. L. Oude Lashof; Geert H. Groeneveld; Johannes van der Hoeven; Jan Willem C. Alffenaar; Frans G. M. Russel; Frank van de Veerdonk; Roger J. M. Bruggemann

doi:10.1128/AAC.00915-17

Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations

Eline W. Muilwijk^*
, Bart G. J. Dekkers
, Stefanie S. V. Henriet
, Paul E. Verweij
, Bregje Witjes
, Astrid M. L. Oude Lashof
, Geert H. Groeneveld
, Johannes van der Hoeven
, Jan Willem C. Alffenaar
, Frans G. M. Russel
, Frank van de Veerdonk
, Roger J. M. Bruggemann^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50% of patients, that poses a severe threat if not managed properly.

Original language	English
Article number	e00915-17
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	9
DOIs	https://doi.org/10.1128/AAC.00915-17
Publication status	Published - Sept 2017

Keywords

aspergillosis
drug interactions
exposure
influenza
pharmacokinetics
HUMAN LIVER-MICROSOMES
PHARMACOKINETIC INTERACTIONS
CLINICAL-RELEVANCE
METABOLISM
CYP2C19

Access to Document

10.1128/AAC.00915-17

https://europepmc.org/articles/pmc5571297?pdf=renderLicence: Other

Cite this

Muilwijk, E. W., Dekkers, B. G. J., Henriet, S. S. V., Verweij, P. E., Witjes, B., Lashof, A. M. L. O., Groeneveld, G. H., van der Hoeven, J., Alffenaar, J. W. C., Russel, F. G. M., van de Veerdonk, F., & Bruggemann, R. J. M. (2017). Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. Antimicrobial Agents and Chemotherapy, 61(9), Article e00915-17. https://doi.org/10.1128/AAC.00915-17

@article{cb3f2e7c283940018dbfe7140e9cfb61,

title = "Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations",

abstract = "Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50\% of patients, that poses a severe threat if not managed properly.",

keywords = "aspergillosis, drug interactions, exposure, influenza, pharmacokinetics, HUMAN LIVER-MICROSOMES, PHARMACOKINETIC INTERACTIONS, CLINICAL-RELEVANCE, METABOLISM, CYP2C19",

author = "Muilwijk, \{Eline W.\} and Dekkers, \{Bart G. J.\} and Henriet, \{Stefanie S. V.\} and Verweij, \{Paul E.\} and Bregje Witjes and Lashof, \{Astrid M. L. Oude\} and Groeneveld, \{Geert H.\} and \{van der Hoeven\}, Johannes and Alffenaar, \{Jan Willem C.\} and Russel, \{Frans G. M.\} and \{van de Veerdonk\}, Frank and Bruggemann, \{Roger J. M.\}",

year = "2017",

month = sep,

doi = "10.1128/AAC.00915-17",

language = "English",

volume = "61",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "9",

}

TY - JOUR

T1 - Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations

AU - Muilwijk, Eline W.

AU - Dekkers, Bart G. J.

AU - Henriet, Stefanie S. V.

AU - Verweij, Paul E.

AU - Witjes, Bregje

AU - Lashof, Astrid M. L. Oude

AU - Groeneveld, Geert H.

AU - van der Hoeven, Johannes

AU - Alffenaar, Jan Willem C.

AU - Russel, Frans G. M.

AU - van de Veerdonk, Frank

AU - Bruggemann, Roger J. M.

PY - 2017/9

Y1 - 2017/9

N2 - Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50% of patients, that poses a severe threat if not managed properly.

AB - Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50% of patients, that poses a severe threat if not managed properly.

KW - aspergillosis

KW - drug interactions

KW - exposure

KW - influenza

KW - pharmacokinetics

KW - HUMAN LIVER-MICROSOMES

KW - PHARMACOKINETIC INTERACTIONS

KW - CLINICAL-RELEVANCE

KW - METABOLISM

KW - CYP2C19

U2 - 10.1128/AAC.00915-17

DO - 10.1128/AAC.00915-17

M3 - Article

C2 - 28717040

SN - 0066-4804

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 9

M1 - e00915-17

ER -

Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations

Abstract

Keywords

Access to Document

Fingerprint

Cite this